0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

New Pharmaceutical Strategies Devised in Effort to Treat Schizophrenia Effectively With Less Risk

Matthew J. Kleinerman
JAMA. 1990;264(19):2487. doi:10.1001/jama.1990.03450190017005.
Text Size: A A A
Published online

ABSTRACT

FOR SOME patients, the antipsychotic medications now used to treat schizophrenia provide incomplete or no relief of symptoms, or have serious side effects. However, two new drug therapies now under study may help patients who previously have been refractory to treatment, perhaps with fewer adverse effects.

One of these drugs, remoxipride (Merck Sharp & Dohme, West Point, Pa), is a member of a new class of antipsychotics, says Stephen Shuchter, MD, clinical professor of psychiatry at the University of California, San Diego, School of Medicine and principal investigator for the remoxipride clinical trials there.

Dopamine Antagonist  Like other antipsychotic medications, remoxipride is a dopamine antagonist that blocks dopamine receptors in the limbic and nigrostriatal areas of the brain. Neuroleptics usually relieve psychotic symptoms by acting on the limbic area, but, by inactivating the nigrostriatal area, they often lead to the development of parkinsonian symptoms and other side effects.Dopamine binds

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();